Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Mayumi Nakagawa to Papillomavirus Infections

This is a "connection" page, showing publications Mayumi Nakagawa has written about Papillomavirus Infections.

 
Connection Strength
 
 
 
4.992
 
  1. Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019 Aug; 78:8-16.
    View in: PubMed
    Score: 0.604
  2. Ravilla R, Coleman HN, Chow CE, Chan L, Fuhrman BJ, Greenfield WW, Robeson MS, Iverson K, Spencer H, Nakagawa M. Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion. Integr Cancer Ther. 2019 Jan-Dec; 18:1534735419893063.
    View in: PubMed
    Score: 0.583
  3. Coleman HN, Greenfield WW, Stratton SL, Vaughn R, Kieber A, Moerman-Herzog AM, Spencer HJ, Hitt WC, Quick CM, Hutchins LF, Mackintosh SG, Edmondson RD, Erickson SW, Nakagawa M. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother. 2016 May; 65(5):563-73.
    View in: PubMed
    Score: 0.480
  4. Moerman-Herzog A, Nakagawa M. Early Defensive Mechanisms against Human Papillomavirus Infection. Clin Vaccine Immunol. 2015 Aug; 22(8):850-7.
    View in: PubMed
    Score: 0.456
  5. Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN. Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol. 2015 Jul; 22(7):679-87.
    View in: PubMed
    Score: 0.453
  6. Nakagawa M, Spencer HJ, Coleman HN, Greenfield WW. Distribution of human papillomavirus (HPV) types and anti-HPV T-cell immune responses among different racial/ethnic groups in Central Arkansas. J Ark Med Soc. 2013 Jan; 109(8):160-3.
    View in: PubMed
    Score: 0.385
  7. Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer Immunol Immunother. 2012 Jan; 61(1):63-70.
    View in: PubMed
    Score: 0.350
  8. Nakagawa M, Gupta SK, Coleman HN, Sellers MA, Banken JA, Greenfield WW. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 e6 antigens in women being studied for abnormal pap smear results. J Low Genit Tract Dis. 2010 Apr; 14(2):124-9.
    View in: PubMed
    Score: 0.318
  9. Wang X, Moscicki AB, Tsang L, Brockman A, Nakagawa M. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol. 2008 Jun; 15(6):937-45.
    View in: PubMed
    Score: 0.278
  10. Nakagawa M, Kim KH, Gillam TM, Moscicki AB. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol. 2007 Feb; 81(3):1412-23.
    View in: PubMed
    Score: 0.252
  11. Nakagawa M, Kim KH, Moscicki AB. Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin Diagn Lab Immunol. 2005 Aug; 12(8):1003-5.
    View in: PubMed
    Score: 0.230
  12. Dai L, Wilson LG, Nakagawa M, Qin Z. Coinfections with additional oncoviruses in HPV+ individuals: Status, function and potential clinical implications. J Med Virol. 2024 Jan; 96(1):e29363.
    View in: PubMed
    Score: 0.206
  13. Nakagawa M, Viscidi R, Deshmukh I, Costa MD, Palefsky JM, Farhat S, Moscicki AB. Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol. 2002 Jul; 9(4):877-82.
    View in: PubMed
    Score: 0.186
  14. Wang X, Che Y, Chen B, Zhang Y, Nakagawa M, Wang X. Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice. Int Immunopharmacol. 2018 Mar; 56:249-260.
    View in: PubMed
    Score: 0.137
  15. Farhat S, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer. 2009 May; 19(4):508-12.
    View in: PubMed
    Score: 0.075
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.